Volume 26, Number 3—March 2020
Research Letter
Coccidioidomycosis Skin Testing in a Commercially Insured Population, United States, 2014–20171
Table
Characteristic | Value | Diagnosis or procedure codes |
---|---|---|
Age, median, y (range) | 46 (2–85) | |
0–17 | 20 (5) | |
18–34 | 73 (18) | |
35–44 | 67 (16) | |
45–54 | 105 (26) | |
55–64 | 116 (29) | |
>65 |
26 (6) |
|
Sex | ||
M | 164 (40) | |
F |
243 (60) |
|
Primary beneficiary’s residence | ||
California | 367 (90) | |
Arizona | 16 (4) | |
Other or unknown state |
24 (6) |
|
Underlying conditions | ||
Immune-mediated inflammatory disease | 44 (11) | ICD-9-CM codes 555, 556, 696.0, 696.1, 696.8, 714.0, 714.2; ICD-10-CM codes K50, K51, L40, M023, M05, M06, M08, M33, M352, M45 |
Chronic obstructive pulmonary disease | 40 (10) | ICD-9-CM codes 490–492, 494, 496; ICD-10-CM codes J41–J44 |
Diabetes | 39 (10) | ICD-9-CM codes 249–250; ICD-10 codes E08–E11 |
HIV/AIDS | 5 (1) | ICD-9-CM code 042; ICD-10-CM code B20 |
Solid organ or stem cell transplant | 4 (1) | ICD-9-CM codes V42 (excluding V42.3–V42.5), 996.8; ICD-10-CM codes T86, Z94 (excluding Z94.5– Z94.7) |
Hematologic malignancy |
4 (1) |
ICD-9-CM codes 200–208; ICD-10-CM codes C81–C86, C88, C90–C96 |
Fungal laboratory testing in the 3 mo before skin test | ||
Coccidioidomycosis serologic test | 20 (5) | CPT codes 86331, 86171, 86635 |
Fungal culture | 5 (1) | CPT codes 87101, 87102, 87103, 87106, 87107 |
Fungal smear |
11 (3) |
CPT codes 87205, 87206, 87210 |
Fungal laboratory testing on the day of or in the 3 mo after skin test | ||
Coccidioidomycosis serologic test | 63 (15) | CPT codes 86331, 86171, 86635 |
Fungal culture | 34 (8) | CPT codes 87101, 87102, 87103, 87106, 87107 |
Fungal smear | 42 (10) | CPT codes 87205, 87206, 87210 |
*Values are no. (%) except as indicated. CPT, Current Procedural Terminology; ICD-9-CM, International Classification of Diseases, 9th Revision, Clinical Modification; ICD-10-CM, International Classification of Diseases, 10th Revision, Clinical Modification.
1This work was presented in part at the 63rd Annual Coccidioidomycosis Study Group Conference, Sacramento, California, USA, April 5–6, 2019.
Page created: February 20, 2020
Page updated: February 20, 2020
Page reviewed: February 20, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.